Search results

Skip to results

Area of interest

Area of interest

Type

Type

Status

Status

Last updated

Last updated

Guidance programme

Advice programme

Showing 601 to 615 of 1688 results for carers

  1. Tucatinib with trastuzumab and pertuzumab for maintenance treatment of HER2-positive unresectable advanced breast cancer after induction chemotherapy [ID6402]

    Awaiting development [GID-TA11487] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  2. Durvalumab with enfortumab vedotin for neoadjuvant and adjuvant treatment of muscle-invasive bladder cancer when cisplatin is unsuitable [ID6445]

    Awaiting development [GID-TA11517] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  3. Zolbetuximab with nab-paclitaxel and gemcitabine for untreated claudin 18.2-positive metastatic pancreatic cancer [ID6444]

    Awaiting development [GID-TA11560] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  4. Osimertinib for neoadjuvant treatment of EGFR mutation-positive resectable non-small-cell lung cancer ID 6472

    Awaiting development [GID-TA11589] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  5. Dupilumab for treating eosinophilic oesophagitis in children 1 to 11 years ID 6492

    Awaiting development [GID-TA11383] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  6. Idecabtagene vicleucel for treating relapsed or refractory multiple myeloma after 2 to 4 therapies ID 6491

    Awaiting development [GID-TA11075] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  7. Neuro-Cells stem-cell treatment for traumatic spinal cord injury [TS ID 12048]

    Awaiting development [GID-TA11629] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  8. STS101 for treating acute migraine TS ID 11782

    Awaiting development [GID-TA11147] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  9. Nivolumab with ipilimumab for adjuvant treatment of localised renal cell carcinoma TS ID 9659

    Awaiting development [GID-TA11111] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  10. Treprostinil diethanolamine for treating pulmonary arterial hypertension TS ID 11772

    Awaiting development [GID-TA11123] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  11. Nitazoxanide for treating the common cold in people 12 years and over TS ID 10548

    Awaiting development [GID-TA11128] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  12. Zamtocabtagene autoleucel for treating relapsed or refractory diffuse large B-cell lymphoma after 2 or more therapies TS ID 10765

    Awaiting development [GID-TA11050] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  13. REGN5458 for treating relapsed or refractory multiple myeloma TS ID 10443

    Awaiting development [GID-TA11052] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  14. Estetrol for treating vasomotor symptoms associated with the menopause in people aged 40 to 65 ID4037

    Awaiting development [GID-TA11059] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development

  15. Cenobamate for adjunctive treatment of primary generalised tonic-clonic seizures in epilepsy TS ID 10214

    Awaiting development [GID-TA11069] Expected publication date: TBC

    Technology appraisal guidance
    Awaiting development